aot2022v55i2

More documents

Recommendations

Info

Acta Oncologica Turcica 2022; 55: 93-10296Table 1. Demographic and clinicopathological characteristics of patientsMedian (Minimum;Maximum) N=70 (%)Age of diagnosis (years) 56 (22;92)Gender Female 28 (40%)Male 42 (60%)Age <65 years 48 (68.6%)≥65 years 22 (31.4%)Smoking Female Yes 9 (32.1%)No 19 (67.9%)Male Yes 34 (80.9%)No 8 (19,1%)Alcohol No 55 (78.6%)Yes 15 (21.4%)Comorbidity No 36 (51.4%)Yes 34 (48.6%)ECOG-PS 0 18 (25.7%)1 40 (57.1%)2 12 (17.2%)Tumor location 2/3 anterior of the tongue 19 (27.1%)1/3 posterior of the tongue 46 (65.7%)Both sides 5 (7.1%)Pathological T Tx 8 (16%)T1 11 (22%)T2 21 (42%)T3 9 (18%)T4a 1 (2%)Pathological N Nx 11 (22%)N0 14 (28%)N1 20 (40%)N2a 4 (8%)N2b 1 (2%)Extranodal extension Negative 20 (40%)Positive 5 (10%)Unknown 25 (50%)Perineural invasion No 11 (22%)Yes 18 (36%)Unknown 21 (42%)LymphovascularinvasionNo 17 (34%)Yes 10 (20%)Unknown 23 (46%)Grade Grade1 16 (22.9%)Grade2 32 (45.7%)Grade3 2 (2.9%)Unknown 20 (28.5%)Neoadjuvant therapy Yes 9 (12.9%)No 61 (87.1%)Adjuvant therapy No 17 (24.3 %)RT 9 (12.8%)CRT 44 (62.9%)ECOG PS: Eastern Cooperative Oncology Group Performance Status, RT: Radiotherapy, CRT: chemoradiotherapySurgical pathology reports of 50 patients could be accessed.www.actaoncologicaturcica.comCopyright©Ankara Onkoloji Hastanesi
Acta Oncologica Turcica 2022; 55: 93-10297Figure 1. Kaplan-Meier Curve of Overall Survivalby Tumor LocationFigure 3. Kaplan-Meier Curve of Overall Survivalby ECOG-PS(1.1-8.2) years in female patients and was notreached in male patients (p=0.075).Figure 2. Kaplan-Meier Curve of Overall Survivalby Smokingyears in patients <55 years of age, 4 (3.2-4.9)years in patients aged ≥55 years (p=0.450).The median DFS was 4.0 (0.1-7.9) years inpatients <65 years of age, 4.5 (1.9-7.2) yearsin patients aged ≥65 years (p=0.951). Therewas no statistically significant differencebetween the groups in terms of median OS andDFS.The median DFS was 5.9 (3.7-8.1) years inmale patients and 2.2 (1.2-3.2) years infemales (p=0.349). The median OS was 4.1www.actaoncologicaturcica.comWhen the patients were divided into twogroups according to tumor location, medianOS could not be reached in the 2/3 anteriortumors of the tongue, while the median OSwas 6.9 (2.7-9.8) years in the 1/3 posteriortumors of the tongue (p=0.046) (Figure-1).While the median DFS could not be reachedin the anterior 2/3 anterior tumors of thetongue, the median DFS was 3.8 (1.0-6.7)years in the 1/3 posterior tumors of the tongue(p=0.073). While the median OS was 7.2 (6.8-7.6) years in those who did not receiveadjuvant therapy, it did not reach the medianin those who received adjuvant therapy (RT orCRT) (p=0.877). While the median DFS was6.5 (0.2-13.2) years in those who did notreceive adjuvant therapy, it was 3.9 (1.7-6.1)years in those who received adjuvant therapy(RT or CRT) (p=0.317).While the median OS was 3.1 (0.5-5.8) yearsin smokers, the median OS could not bereached in non-smokers (p=0.019) (Figure-2).While the median OS was 1.6 (0.9-2.2) yearsin the group of patients with ECOG PS of 2,the median OS could not be reached inCopyright©Ankara Onkoloji Hastanesi
Page 2 and 3: Acta Oncologica Turcica 2022EDITORI
Page 4 and 5: Acta Oncologica Turcica 20222should
Page 6 and 7: Acta Oncologica Turcica 20224KEYWOR
Page 8 and 9: Acta Oncologica Turcica 20226found
Page 10 and 11: Quality of Life Assessment with EOR
Page 12 and 13: Acta Oncologica Turcica 2022; 55: 7
Page 17: Acta Oncologica Turcica 2022; 55: 7
Page 82 and 83:
Acta Oncologica Turcica 2022; 55: 1
Page 84 and 85:
Page 86 and 87:
Page 88:
Page 91 and 92:
Page 93 and 94:
Page 95 and 96:
Page 97 and 98:
Page 99 and 100:
Page 101 and 102:
Page 103 and 104:
Page 105 and 106:
Page 107 and 108:
Page 109 and 110:
Page 111 and 112:
Page 113 and 114:
Page 115 and 116:
Page 117 and 118:
Page 119 and 120:
Page 121 and 122:
show all

aot2022v55i2

Create successful ePaper yourself

Delete template?

Save as template?